Table 1.

Baseline characteristics and parameter changes of 110 patients after androgen deprivation therapy

Variable	Baseline	After ADT	P-value
PSA (ng/mL)	64.89±21.15*	8.01±3.17	< 0.01
Prostate volume (mL)	36.65±14.59*	19.49±12.47	< 0.01
IPSS total score	17.45±8.56*	12.21±7.6	0.04
IPSS voiding subscore	9.83±6.11*	6.70±5.06	0.02
IPSS storage subscore	7.65±3.75	5.54±3.48	0.29
Quality of life score change	4.06±1.98	3.15±0.97	0.07
Functional bladder capacity change (mL)	309.36±107.54	314.03±110.03	0.83
Day time voiding frequency	6.01±0.79	5.93±0.80	0.29
Night time voiding frequency	2.82±0.86	2.73±0.91	0.63
Qmax (mL/sec)	8.62±5.43	11.50±4.71*	0.04
Postvoid residual volume (mL)	60.41±20.43	31.07±10.42*	0.02

Values are presented as mean±standard deviation.

ADT, androgen deprivation therapy; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; Qmax, maximal uroflow rate.

^*P<0.05, baseline vs. after ADT.